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The New Zealand obese (NZO) mouse strain shares with
the related New Zealand black (NZB) strain a number of
immunophenotypic traits. Among these is a high propor-
tion of B-1 B lymphocytes, a subset associated with au-
toantibody production. Approximately 50% of NZO/HlLt
males develop a chronic insulin-resistant type 2 diabetes
syndrome associated with 2 unusual features: the pres-
ence of B lymphocyte–enriched peri-insular inﬁltrates and
the development of anti-insulin receptor autoantibodies
(AIRAs). To establish the potential pathogenic contribu-
tionsofBlymphocytesandAIRAsinthismodel,adisrupted
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immunoglobulin heavy chain gene (Igh-6) congenic on the
NZB/BlJ background was backcrossed 4 generations into
the NZO/HlLt background and was then intercrossed to
produce mice that initially segregated for wild-type ver-
sus the mutant Igh-6 allele and thus permitted compari-
son of syndrome development. A new ﬂow cytometric as-
say (AIRA binding to transfected Chinese hamster ovary
cells stably expressing mouse insulin receptor) showed IgM
and IgG subclass AIRAs in serum from Igh-6 intact males,
but not in Igh-6null male serum. However, the absence of
B lymphocytes and antibodies distinguishing mutant from
wild-type males failed to signiﬁcantly affect diabetes-free
survival.TheIgh-6null malesgainedweightlessrapidlythan
wild-typemales,probablyaccountingforaretardation,but
not prevention, of hyperglycemia. Thus, AIRA and the B-
lymphocyte component of the peri-insulitis in chronic di-
abetics were not essential either to development of insulin
resistance or to eventual pancreatic beta cell failure and
loss. A new substrain, designated NZL, was generated by
inbreedingIgh-6wild-typesegregants.CurrentlyattheF10
generation, NZL mice exhibit the same juvenile-onset obe-
sity as NZO/HlLt males, but develop type 2 diabetes at a
higherfrequency(>80%).Also,unlikeNZO/HlLtmicethat
aredifﬁculttobreed,theNZL/Ltstrainbreedswellandthus
offers clear advantages to obesity/diabetes researchers.
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New Zealand Obese (NZO) Mice; Type 2 Diabetes
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NewZealandobese(NZO)isaninbredmousestrainderived
in New Zealand from outbred stock from the Imperial Cancer
Research Fund Laboratories in London [1]. NZO mice have
been studied primarily as a mouse model of obesity-induced
insulin-resistantdiabetes[2].MalesoftheNZO/HlLtstrainde-
velopdiabetesatafrequencyof40%to50%whereasNZO/HlLt
females develop marked obesity without diabetes [3]. Because
of the early development of obesity, the strain is difﬁcult
to breed and has not been widely studied. Thus, despite
the relatedness of the NZO strain to the autoimmune-prone
New Zealand black (NZB) and New Zealand white (NZW)
strains, only limited analysis of the immune system of NZO
micehasbeenreported[4,5].ThesestudiesindicatedthatNZO
shared some of the classic autoimmune abnormalities found in
the NZB strain, and suggested that the development of diabetes
isassociatedwithautoimmunity.Amongtheimmuneanomalies
reported were the development of immunoglobulin M (IgM)
autoantibodies to native and single-stranded DNA as well as
IgM immune complex deposition in kidney [4]. Another im-
muneanomalysharedwiththeNZBstrainwassplenichypertro-
phy with increased basal unstimulated splenocyte proliferation
in vitro, but reduced mitogen-stimulated proliferation. How-
ever, this hypoproliferative phenotype was reversed by insulin
administration only in NZO, but not in NZB mice [5], suggest-
ing that the immune anomaly in NZO was related to insulin
resistance in these mice. That autoimmunity may contribute, in
part,tothemetabolicsyndromeinNZOmicewassuggestedby
the report that this strain spontaneously develops autoantibod-
ies to the insulin receptor [6]. Recent work from our laboratory
foundahighfrequencyofB1BlymphocytesinNZO/HlLtmice,
a subset associated with autoantibody production [7]. Further-
more, pancreatic histopathology of the peri-insular inﬁltrates
commonly observed in chronically diabetic NZO/HlLt males
showed a higher frequency of B lymphocytes than T lympho-
cytes and included plasma cells (antibody producers) [8]. To
establish whether the type 2 diabetes syndrome developing in
NZO/HlLt males was dependent upon humoral immunity, we
developedanewﬂowcytometry–basedmethodologyfordetect-
ing anti-insulin receptor autoantibody (AIRA) and generated a
B lymphocyte–deﬁcient stock on the NZO strain background
for comparison of syndrome development in the presence ver-
sus absence of AIRAs and other autoantibodies.
METHODS
Mice
NZO/HlLt and C57BL/6J mice were housed in a speciﬁc
pathogen–free (SPF) environment at The Jackson Laboratory.
NZO/HlLt male progeny were aged to 24 weeks, with body
weight measured every 2 weeks and plasma glucose (glucose
analyzer; Beckman Instruments, Palo Alto, CA) measured ev-
ery4weeks.Diabetes(plasmaglucoselevels>250mg/dL)was
50% in NZO males by 24 weeks of age.
All animals were handled in accordance with the guidelines
oftheNationalInstitutesofHealth,andtheInstitutionalAnimal
Care and Use Committee of The Jackson Laboratory.
Generation of a New Recombinant Congenic
Strain (NZL/Lt) Segregating for B-Lymphocyte
Deﬁciency
NZB/BlnJ mice congenic for a disrupted Igh-6 allele on
chromosome 12 encoding the IgM heavy chain [9] (formal
designation NZB,129-Igh-6tm1Cgn) were kindly provided by
Dr.L.D.Shultz(TheJacksonLaboratory)[10].Malesfromthis
stock (at N11) were outcrossed with NZO/HlLt females and F1
females were backcrossedto NZO/HlLt males. In 4 subsequent
backcross cycles, heterozygous Igh-6null carriers were identi-
ﬁedbypolymerasechainreaction(PCR)fortheneomycinresis-
tancecassetteusedingenetargeting.AtN5,heterozygoteswere
intercrossed, and N5F1 Igh-6null homozygotes were identiﬁed
by ﬂow cytometric demonstration of the absence of B220+ B
lymphocytes in peripheral blood (monoclonal antibody [mAb]
clone RA3-6B2; BD PharMingen). Homozygous mice gener-
ated between N5F1 and N5F4 were analyzed. At N5F2, a con-
trol line, now designated NZL, was selected that was wild type
(e.g., NZO alleles) at the Igh-6 locus and at ﬂanking polymor-
phic microsatellite markers distinguishing NZO from NZB.
Analysis of Diabetic Syndrome Progression
Wild-type NZL and NZL-Igh-6null males were accumulated
between N5F1 and N5F4 and longitudinally proﬁled for bi-
weekly changes in body weight (BW) and nonfasting plasma
glucose (PG) determined on a glucose analyzer (Beckman In-
struments, Fullerton, CA). Mice were maintained on a 6% fat-
containingchow(NIH-31;Purina,Richmond,IN)andacidiﬁed
drinking water. Because the immunodeﬁcient NZL-Igh-6null
mice were very susceptible to infections, both genotypes were
maintained in pressurized individually ventilated (PIV) caging
and received sulfamethoxazole thiomethoprim (Goldline Lab-
oratories, Ft. Lauderdale, FL) for 3 days per week. Serum sam-
ples for AIRA analysis from both genotypes were collected at
the 20-week termination point for analysis in the AIRA assay
(see below).
Generation of Chinese Hamster Ovary Mouse
Insulin Receptor–Transfected Cell Line
Full length (α and β chain) mouse insulin receptor (mIR)
cDNA was excised from pMTIII (M. Daniel Lane; Johns
Hopkins, Baltimore, MD) [11] by Not1/Sal1 restrictionROLE OF AIRAs IN TYPE 2 DIABETES 179
digestion and subcloned into pREP4-hygromycin–resistant
mammalian expression vector at Not1/Xho1 sites (Invitrogen,
Carlsbad, CA).
Chinese hamster ovary (CHO) cells (American Type Cul-
tureCollection,Rockville,MD)weretransfectedwith10µgof
thepREP4/mIRconstructusingLipofectAMINEPLUS(Gibco
BRL, Gaithersburg, MD) per manufacturer’s instructions.
Transfected CHO cells were grown in F12K media (Gibco)
with 10% fetal calf serum and selected with 600 µg/mL hy-
gromycin B (Calbiochem, LaJolla, CA). Hygromycin-resistant
clones were screened for IR expression by 125I-insulin–binding
assay [12, 13]. HIR3.5 (Jonathan Whittaker; NYU School of
Medicine, NY, NY), stably transfected NIH 3T3 ﬁbroblasts ex-
pressing 106 human IRs per cell [14], served as a positive con-
trol in the screening experiments. Untransfected parental CHO
cells were used as a negative control to account for any back-
ground expression of endogenous hamster IRs. Clone 36, the
transfected CHO clone with the highest level of mouse IR ex-
pression, was labeled with ﬂuorescein isothiocyanate (FITC)-
labeledinsulin(Sigma,St.Louis,MO)andcellsexpressinghigh
density of IRs were positively sorted using a Becton-Dickinson
ﬂow cytometer (Wayne State University, Detroit, MI). Sorted
cells were subjected twice to limiting dilution until a subclone
(mIR36.11.1) with stable cell surface expression of mIR was
obtained. Subclone mIR36.11.1, untransfected parental CHO
cells, and positive control HIR3.5 were retested for IR expres-
sion by 125I-insulin–binding assay [12, 13].
Functionality of the mIR on the mIR 36.11.1
CHO Cells–Transfected Clone
Speciﬁc binding of 125I-insulin (human recombinant;
Amersham Biosciences, Piscataway, NJ) on mIR36.11.1 and
controlHIR3.5cellswasdeﬁnedbycompetitionwithunlabeled
insulin as previously described [12, 13]. Brieﬂy, 125I-insulin
(50,000cpm,11.36×10−12 M)wasaddedtocells(1×106 per
well)eitheralonetodeterminemaximumbindingorinthepres-
ence of increasing concentrations of unlabeled insulin (10−10
to 10−6 M) in a ﬁnal incubation volume of 1 mL. Following
binding overnight at 4◦C, cells were washed with phosphate-
buffered saline (PBS; JRH Biosciences, Lenexa, MO), and the
amount of bound 125I-insulin in 0.4 N NaOH–treated cells was
counted in a Beckman Gamma 5000 counter (Medical College
of Ohio, Toledo, OH). All samples were done in duplicate.
Speciﬁc binding of biotinylated insulin was also deﬁned by
competition with unlabeled insulin using the ﬂuorescence ac-
tivated cell sorter (FACS) analysis. mIR36.11.1 cells at 5 ×
105 were incubated with 5 × 10−6 M biotinylated insulin (a
gift from Dr. Francis Finn, University of Pittsburg, retired)
either alone to determine maximum binding or in the pres-
ence of increasing concentrations of unlabeled insulin (10−9 to
10−3 M) for 45 minutes on ice followed by washing. The sec-
ondary reagent streptavidin-phycoerythrin (SA-PE; Pharmin-
gen, San Diego, CA) was then added for 45 minutes on ice.
Control cells were treated with 30 µg/mL unlabeled insulin
and SA-PE following the procedure above to determine back-
ground binding. After washing, cells (10,000 per sample) were
analyzed immediately using a Becton-Dickinson ﬂow cytome-
ter (University of Toledo, Toledo, Ohio) to determine the geo-
metric mean ﬂuorescence (GMF) of each sample.
Anti-mIR Antibody Assay Using
mIR-Transfected CHO Cells
and Flow Cytometry
Serum AIRA was quantiﬁed by FACS analysis of mouse
Ig binding to mIR 36.11.1 compared to untransfected CHO
cells. NZO/HlLt sera used in ﬂow cytometry were precipitated
by 25% saturated ammonium sulfate (SAS) to obtain an IgM-
enriched fraction. The supernatant was then subjected to an
additional 45% SAS precipitation and puriﬁed further by pro-
tein A conjugated beads to enrich for IgG antibodies. Sample
binding to untransfected CHO cells was used to establish a
baseline in FACS analysis. Incubation with biotinylated insulin
and SA-PE served as a positive control for staining. Serum
samples were pooled from 5 to 6 mice from each of the fol-
lowing: C57BL/6J female 30 weeks of age, C57BL/6J males
30 weeks of age, NZO/HlLt female 16 to 17 weeks of age,
NZO/HlLt females 34 weeks of age, NZO/HlLt males 16 to
17 weeks of age, and NZO/HlLt males 20 to 28 weeks of age,
all with normal blood glucose levels. An additional group of
9 diabetic males between 20 and 28 weeks of age (plasma
glucose >250 mg/dL) were also analyzed. In a separate set
of experiments serum was collected from 20-week-old male
NZL(poolof5),NZL-Igh-6null (poolof10),andNZOdiabetic
mice (pool of 5). IgM and IgG fractionation on pooled serum
samples was performed using a protein G spin chromatogra-
phy kit (Pierce, Rockford, IL) according to manufacturer’s in-
structions. Fractionated antibody (Ab) was added to 0.5 × 106
cells for 45 minutes on ice, washed off and replaced by sec-
ondary antibody, afﬁnity puriﬁed F(ab’)2 donkey anti-mouse
IgG(H+L)-PE(minimalcross-reactivitywithbovine,chicken,
goat, guinea pig, hamster, horse, human, rabbit, or sheep
serum proteins; Jackson Immunologicals, West Grove, PA).
After an incubation of 45 minutes on ice, cells were washed,
iced, and analyzed immediately using a Coulter Elite ﬂow cy-
tometer (Medical College of Ohio, Toledo, OH) or a Becton-
Dickinson ﬂow cytometer (University of Toledo, Toledo, OH).
No detectable shift was seen with parental or transfected mIR
36.11.1 cells labeled with secondary antibody alone or SA-PE
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Radioimmunoassay with the β Subunit
of the Human IR
AIRAs that were detected by ﬂow cytometry analysis of
Ig-binding to mIR were also detected by radioimmunoassay.
Sera from NZO/HlLt and control mice were used to precipitate
the in vitro transcribed/translated 35S-Met–labeled β subunit
of the human IR. Protein G was applied to precipitate IgG im-
munocomplexes and several washes were preformed to remove
any unbound antigen. Results are expressed in cpm. A rabbit
anti-human IR β subunit polyclonal antisera was used as pos-
itive control (Research Diagnostic, Flanders, NJ) and normal
rabbit serum as negative control.
Statistics
SurvivalstatisticswereperformedusingKaplan-Meieranal-
ysis (STATVIEW; Abacus Software, Palo Alto, CA). Signiﬁ-
canceofdifferencesforotherdatawereanalyzedusingANOVA
with Bonferroni/Dunn correction or the Student’s t test with
signiﬁcant differences set at a P value of less than .05.
RESULTS
Functionality of the mIR on the
mIR36.11.1-Transfected CHO Clone
In order to develop an assay for the detection of antibodies
totheIR,wetransfectedCHOcellswithanIR-codingplasmid.
IR-expressing cells were screened by 125I-insulin–binding as-
say [12, 13], sorted by ﬂow cytometry using FITC-insulin,
cloned, and subcloned by limiting dilution until a stable
IR-expressing CHO transfectant clone was isolated. Positive
control HIR3.5 and mIR-transfected CHO subclone 36.11.1
(mIR36.11.1) cells bound 125I-insulin to a comparable extent
andsigniﬁcantlymoreeffectivelythanuntransfectedCHOcells
(P <. 03) (Figure 1A).
The speciﬁc binding of 125I-insulin to the IR on HIR3.5 and
mIR36.11.1 cells was analyzed by competition with increas-
ing concentrations of unlabeled insulin (10−10 to 10−6 M). As
shown in Figure 1B (HIR3.5) and Figure 1C (mIR36.11.1), in-
creasing concentrations of unlabeled insulin competed for the
insulin binding site and prevented binding of a constant con-
centration of 125I-insulin. 125I-insulin binding was completely
inhibited with 2 × 10−6 M unlabeled insulin in both cell lines.
Furthermore, based on Scatchard analysis, the HIR3.5 cell line
expressed0.5×106 IRspercellascomparedtothemIR36.11.1
clone that expressed 2 × 106 IRs per cell.
Incomparisontotheﬂowcytometricproﬁleofuntransfected
CHO cells, a rightward shift of ﬂuorescence intensity was
observed following labeling of the stable mIR36.11.1 transfec-
tant subclone with biotinylated insulin and SA-PE, conﬁrming
cell surface expression of mIR (Figure 1D). Speciﬁc binding
of biotinylated insulin was conﬁrmed by competitive binding
in the presence of increasing concentrations of unlabeled
insulin (10−9 to 10−3 M). Unlabeled insulin competed with
biotinylated insulin for the insulin binding site on mIR36.11.1
cells (Figure 1E). Binding of biotinylated insulin was com-
pletely inhibited in the presence of 5 × 10−4 M unlabeled
insulin (Figure 1E). Overall, the results from Figure 1 show
that mIR36.11.1 cells express IR (Figure 1A and D) com-
parable to that expressed in the positive-control HIR3.5 cells
(Figure 1A and Scatchard results) and insulin speciﬁcally
binds the IR expressed in mIR36.11.1 cells (Figure 1C and E).
Furthermore, the transfected IR in mIR36.11.1 was tyrosine
phosphorylated in the presence of insulin (data viewable at
the website http://mbc.pharm.utoledo.edu/mbc/mfm.html),
indicating that IR in mIR36.11.1 cells is functionally capable
of insulin signal transduction.
AIRAs in NZO Mice
The use of the IR-transfected CHO cell system permitted
conﬁrmation of the previous report of low-afﬁnity IgM AIRAs
present in NZO serum [6]. Figure 2A (extreme right hand bars)
documents that the enriched IgM fraction (IgM concentration
9.7 µg/mL) from NZO/HlLt males at 16 to 17 weeks of age
contained AIRAs.
Most pathological autoimmune antibodies undergo a class
switch from IgM to IgG isotypes. Therefore, supernatants from
25% SAS cuts were precipitated with 45% SAS and this frac-
tion was passed over protein A columns to obtain samples
enriched in IgG. The major protein peak of the acid eluate
was collected in a single fraction for all samples except the
sample from diabetic NZO/HlLt males, which was sufﬁciently
large to collect in multiple fractions. Speciﬁc AIRA was de-
tected in the diabetic 20- to 28-week NZO/HlLt male pool only
in the leading fraction from the column that had a relatively
low Ig concentration (e.g., IgM 1.3 µg/mL, IgG1 14 µg/mL)
(Figure 2A). However, IgG AIRA was not present in age-
matched (20- to 28-week) normoglycemic NZO/HlLt male
micethathadmorethandoubletheamountofIgG1(36µg/mL).
Nor was IgG AIRA detected in any other tested pools when
comparedtobackgroundB6mice(Figure2A).Whenimmuno-
precipitate fractions (IgG enriched) were tested in a radioim-
munoassay with 35S-Met–labeled recombinant β chain of the
human IR, only the NZO/HlLt serum obtained from diabetic
males contained signiﬁcant amounts of AIRAs (Figure 2B).
(Diabetic 20- to 28-week NZO/HlLt male versus normal 20- to
28-week NZO/HlLt male, P <. 0005; diabetic 20- to 28-week
versus 30-week C57BL/6J males, P <. 0009). Therefore, the
same results on IgG-enriched AIRAs in diabetic NZO/HlLt
male mice were obtained in 2 independent assay systems.ROLE OF AIRAs IN TYPE 2 DIABETES 181
FIGURE 1
(A) CHO untransfected parental cells, mouse IR–transfected CHO subclone 36.11.1 (mIR36.11.1), and positive control, human
IR–transfected HIR3.5 cells (x-axis) were analyzed for IR expression by 125I-insulin binding assay [12, 13]. ‘Total 125I-insulin
binding’ was determined by the following calculation: (counts per minute 125I-insulin bound per 106 cells per well/50,000 cpm
125I-insulin added per well) and is presented by bound 125I-insulin/total 125I-insulin (B/T) on the y-axis. Duplicate wells of each
cell type were analyzed and the standard deviation was no greater than 15%. (B and C) Duplicate wells of HIR3.5 cells (B,1×
106 per well) and mIR36.11.1 cells (C,1× 106 per well) were tested for speciﬁc binding of 125I-insulin by competition with
increasing concentrations of unlabeled insulin (10−10 to 10−6 M). (D) CHO parental cells (solid line) and mIR36.11.1-transfected
cells (dotted line) were labeled with biotinylated insulin and strepavadin-phycoerythrin (SA-PE) and analyzed by ﬂow cytometry.
(E) mIR36.11.1–transfected cells at 5 × 105 were labeled with biotinylated insulin either alone or in the presence of increasing
concentrations of unlabeled insulin (10−9 to 10−3 M), followed by secondary reagent SA-PE. The y-axis is the [(geometric mean
ﬂuorescence (GMF) − GMF0 (background GMF of unlabeled insulin and SA-PE))/(GMFmax (maximum binding of biotinylated
insulin and SA-PE) − GMF0)] as determined by ﬂow cytometry analysis. This graph is representative of 2 experiments.
Furthermore, at least some NZO/HlLt AIRAs are cross reac-
tive, because AIRAs from diabetic NZO/HlLt males bound to
the β chain of the human IR.
B Lymphocyte–Deﬁcient NZL-Igh-6null Mice
Do Not Express AIRAs
In order to determine if AIRAs are pathogenic, NZB/BlnJ
mice congenic for a disrupted Igh-6 allele on chromosome 12
encodingtheIgMheavychain[9]werecrossedwithNZO/HlLt
mice as described above to obtain NZL-Igh-6null mutant and
NZL wild-type that express NZO Igh-6 alleles. Analysis of
serum IgM and IgG fractions obtained from NZL wild-type,
NZL-Igh-6null, and NZO males is shown in Figure 3A.A se x -
pected, B cell–deﬁcient NZL-Igh-6null mice did not express
either IgM or IgG AIRAs whereas wild-type NZL and NZO
mice both expressed IgM, and to a lesser extent IgG, AIRAs
(Figure 3A).182 M. F. MCINERNEY ET AL.
FIGURE 2
(A) CHO parental cells (open bars) and mIR36.11.1 (solid bars) were labeled with either 2nd antibody alone [F(ab’)2 donkey
anti-mouse IgG (H + L)-PE] or an IgG-enriched serum fraction (45% SAS cut of 25% SAS supernatant passed over protein A
column) and 2nd antibody. IgG-enriched serum fractions were obtained from pools of mice (5 to 6 mice): 30-week-old female or
male C57BL/6J mice (B6 F 30 wks, B6 M 30 wks); 16- to 17-week-old female or male NZO mice (NZO F 16-17 wks, NZO M
16-17 wks); 34-week-old female NZO mice (NZO F 34 wks); and 20- to 28-week-old NZO male mice either normoglycemic or
diabetic (9 mice in the diabetic pool) (NZO M 20-28 wks norm, NZO M 20-28 wks diab). IgG1 concentrations are given in
parentheses on the graph label on the x-axis for each group tested as an indicator of relative immunoglobulin concentrations. A
25% SAS IgM–enriched fraction, from the 16- to 17-week-old male NZO pool, was also tested and is labeled on the x-axis of the
graph as NZO M 16-17 wks (IgM). The IgM concentration of this 25% SAS fraction from 16- to 17-week-old NZO males was
9.7 µg/mL (see parentheses). The y-axis is the mean ﬂuorescence intensity. The IgG results are representative of duplicate
samples and the IgM results are representative of 2 experiments. (B) Immunoprecipitation of 35S-Met–labeled β subunit of the
human IR by serum fractions from control female and male C57BL/6J mice and female and male NZO nondiabetic and diabetic
mice of various ages as described in A above. Protein G was applied to precipitated IgG-enriched immunocomplexes. Results are
expressed as cpm (mean ± SD) of at least 2 independent sets of experiments performed in triplicate. ∗Signiﬁcance (P <. 0009)
for the difference between diabetic male NZO mice and other strains of mice (C57BL/6J) as well as nondiabetic male and female
NZO mice (Student’s t test).
B-Lymphocyte Deﬁciency Retards, But Does
Not Prevent, Diabetes in NZL Males
The genome of the NZL strain (selected for the ab-
sence of the targeted Igh-6 gene and closely linked alle-
les deriving from 129S2/SvPas on chromosome 12) should
derive approximately 97% of its genome from NZO and
3% from the NZB donor strain. The NZL genome was
typed at F9 for 38 informative MIT microsatellite mark-
ers (Research Genetics, Huntsville, AL) and 116 informative
singlenucleotidepolymorphisms(SNPs;KBioscience,Oxford,
England). Although analytic gaps remain on some chromo-
somes, most of the genome scanned is NZO derived. NZB-
derived genome was found only on Chromosome 9 (Mb 34 to
103) and Chromosome 18 (Mb 55 to 80). A map is viewable
athttp://www.jax.org/staff/leiter/labsite/type2.html.Consistent
with the genome scan data, development of severe obesity inROLE OF AIRAs IN TYPE 2 DIABETES 183
FIGURE 3
(A) Enriched IgM and IgG serum fractions were obtained from 20-week-old male NZL wild type (designated as NZL+/+, pool
of 5), NZL-Igh-6null (designated as NZL−/−, pool of 10), and diabetic NZO mice (pool of 5). mIR 36.11.1 cells were labeled
with either 2nd antibody alone [ F(ab’)2 donkey anti-mouse IgG (H + L)-PE] or an IgM- (solid bars) or IgG- (open bars)
enriched serum fraction (protein G spin chromatography kit) and 2nd antibody and analyzed by ﬂow cytometry. The y-axis is the
mean ﬂuorescence intensity. (B to D) NZL wild-type males are represented by the open square whereas NZL-Igh-6null males are
represented by the open circles. (B) Comparative changes in body weight in grams (g, mean BW ± SEM) of NZL and
NZL-Igh-6null males. (C) Comparative changes in plasma glucose (mean PG ± SEM) in NZL and NZL-Igh-6null males. Values
above 250 mg/dL are considered diabetic. (D) Onset of diabetes is shown as percent survival regression analysis. There is no
signiﬁcant difference between the 2 genotypes for diabetes incidence. n = 14 for NZL and n = 19 for NZL-Igh-6null males.
NZL males (and females, data not shown) was typical of that
observed in NZO/HlLt males. NZL-Igh-6null males, although
markedly obese as well, weighed signiﬁcantly less between
8 and 16 weeks of age (P <. 01) (Figure 3B). Both NZL
wild-typeandIgh-6null mutantmalesdevelopedmaturity-onset
hyperglycemia (Figure 3C). At the 8-week sampling, the NZL
wild-typemean wassigniﬁcantlyhigherthanthemutantmean;
however,themeansdidnotdifferatthelatertimepoints.Ofthe
groups shown in Figure 3C, 13 of 14 wild-type males (93%)
and 15 of 19 Igh-6null males (79%) exhibited hyperglycemia184 M. F. MCINERNEY ET AL.
>250 mg/dL at the 20-week sampling point. These frequen-
cies are higher than the 50% frequency of diabetes observed in
standard NZO/HlLt males [15]. Diabetes-free survival analysis
showednosigniﬁcantdifferencesbetweenthe2genotypes(Fig-
ure 3D). Hence, elimination of humoral autoimmunity slightly
retardedbutdidnotpreventdevelopmentofhyperglycemia.Al-
though NZL wild-type mice of both sexes did not differ from
standardNZO/HlLtmiceintermsofrapiddevelopmentofjuve-
nileobesityandmaturity-onsetdevelopmentofhyperglycemia,
a major difference was observed in reproductive performance.
Whereas40%orfewerofNZOmatingswereproductive,almost
all NZL pair matings established at weaning were productive.
Thus, the recombinant congenic strain exhibits reproductive
vigor that makes this strain much easier to breed.
The results in Figure 3 show that the absence of B lympho-
cytesandcorrespondinglyAIRAsdidnotprotectNZL-Igh-6null
mice from the development of diabetes. Therefore, AIRAs are
notessentialforthepathogenicityassociatedwithinsulinresis-
tance and hyperglycemia in type 2 diabetes in the NZL mouse.
DISCUSSION
Previouslypublishedpreliminaryresultsshowedthatasmall
cohort of B lymphocyte–deﬁcient NZL-Igh-6null males did not
transit to overt diabetes [7]. However, 2 factors indicated cau-
tion in interpretation of this ﬁnding. First, diabetes frequency
in standard NZO/HlLt males is only 50%. Therefore, the small
sample size of B lymphocyte–deﬁcient males (n = 4) available
for anlaysis was inconclusive. Second, these immunodeﬁcient
males were highly susceptible to infections, with all 4 dying
of undiagnosed illness before 20 weeks of age. It has been our
further experience maintaining the NZO and NZL strains that
the males are susceptible to urogenital tract infections, sperm
plugs, and pyelonephritis. We avoided these complications in
the present study by supplementing drinking water with an an-
tibioticandmaintainingbreedingstockandagingmalesinpres-
surized, individually ventilated cages. Under these conditions,
a group of 19 NZL-Igh-6null males were produced for aging
to 20 weeks without age-associated loss in body weight. With
the larger group size, we failed to conﬁrm the preliminary ob-
servation that B-lymphocyte deﬁciency signiﬁcantly protected
against eventual development of diabetes. A signiﬁcant retar-
dation of plasma glucose rise was observed at the 8-week sam-
pling.Althoughmeanplasmaglucoselevelwasalsoloweratthe
12-and16-weekintervals,overalldiabeticfrequenciesattained
by 20 weeks were not signiﬁcantly different between geno-
type (NZL 93%, NZL-Igh-6null 79%). This result is consistent
with an earlier ﬁnding in another mouse diabesity model, the
C57BLKS/J-Leprdb mouse.Numerousstudieshaddocumented
immune anomalies associated with this strain background
susceptibility to diabesity; however, elimination of T- and B-
lymphocyte components by genetic means only retarded sever-
ity without preventing establishment of chronic hyperglycemia
[16].Similarily,inthecurrentstudy,B-lymphocyteimmunode-
ﬁciency only retarded, but failed to prevent, the ultimate devel-
opment of diabesity in NZL-Igh-6null males maintained in PIV
cagingwithantibioticsupplementtopreventinfections.Hence,
we conclude that our initial ﬁnding of suppressed diabesity [7]
likely reﬂected the compromised health status (including se-
vere pyelonephritis) of the initial small group of males in the
absence of special procedures to protect against infections. In-
terestingly, diabetes development in NZL males achieves the
samehighfrequencyasthe(NZO×NON)F1hybridmale[17].
This increased penetrance of diabesity, coupled with the im-
proved reproductive performance despite comparable obesity,
makes the new NZL strain (without the Igh-6null mutation) an
attractive substitute for the NZO/HlLt strain.
The presence of low afﬁnity IgM AIRAs in the sera of male
NZO mice has been reported [6]. Using the mIR-transfected
CHO cell system (mIR36.11.1) and ﬂow cytometry, the pres-
ence of AIRAs in sera from young male NZO/HlLt was con-
ﬁrmed.Inserafrom16-to17-week-oldNZO/HlLtmales,when
thediabetesincidenceisabout10%,AIRAswerepresentinthe
IgM-enriched25%SASprecipitate,butnotintheIgG-enriched
protein A eluate. This indicates that the initial appearance of
AIRAsinNZO/HlLtmalesisprimarilyintheformofIgM.The
presenceofIgGAIRAactivityintheseraofdiabeticNZO/HlLt
males by ﬂow cytometry and radioimmunoassay, and its ab-
sence in mature normoglycemic NZO/HlLt males, appeared to
correlateAIRAactivitywiththedevelopmentoftype2diabetes.
In humans, AIRAs are associated with a rare type B syndrome
of extreme insulin resistance. AIRAs block insulin binding and
mimic the biological effects of insulin leading to insulin re-
sistance and receptor desensitization [18, 19]. Recently, it was
shown in a human patient that AIRAs produced insulin resis-
tance by desensitizing signaling through the IR via inducing a
stable association of the IR with IR substrates 1 and 2 [20]. In
summary, comparison of NZL/Lt males with and without the
ability to produce AIRAs has established that although these
autoantibodies may be useful as markers of the disease state,
AIRAs are not essential for development of type 2 diabetes in
this model.
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